A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor-Reference-Cited by-同舟云学术

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor

Published:2011-01 Issue:1 Volume:3 Page:38-48
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Emanuel Stuart L.,Engle Linda J.,Chao Ginger,Zhu Rong-Rong,Cao Carolyn,Lin Zheng,Yamniuk Aaron P.,Hosbach Jennifer,Brown Jennifer,Fitzpatrick Elizabeth,Gokemeijer Jochem,Morin Paul,Morse Brent A.,Carvajal Irvith M.,Fabrizio David,Wright Martin C.,Das Gupta Ruchira,Gosselin Michael,Cataldo Daniel,Ryseck Rolf P.,Doyle Michael L.,Wong Tai W.,Camphausen Raymond T.,Cload Sharon T.,Marsh H. Nicholas,Gottardis Marco M.,Furfine Eric S.

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/mabs.3.1.14168

Reference48 articles.

1. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design

2. The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

3. Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

4. Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody

5. Construction and Production of an IgG-Like Tetravalent Bispecific Antibody for Enhanced Therapeutic Efficacy

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1;Biomolecules;2023-03-31

2. Discovery of a Non-competitive TNFR1 Antagonist Affibody with Picomolar Monovalent Potency That Does Not Affect TNFR2 Function;Molecular Pharmaceutics;2023-03-10

3. New insights on Pseudomonas aeruginosa exotoxin A-based immunotoxins in targeted cancer therapeutic delivery;Therapeutic Delivery;2023-01

4. Emerging Trends, Challenges, and Opportunities in Protein Therapeutics;Protein-based Therapeutics;2023

5. Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity;International Journal of Molecular Sciences;2022-12-13